1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 1: 
Values of cerebral blood flow (CBF), cerebral blood volume (CBV), mean transit time (MTT), and mean diffusivity 〈D〉 for the entire volume of enhancing tumor pre- and postdexamethasone treatment for the 10 patients participating in this study
Patient No.Enhancing Tumor
CBF (mL/100 g/min)CBV (mL/100 g)MTT (s)<D> (×10−6 mm2/s)
PresteroidsPoststeroidsPresteroidsPoststeroidsPresteroidsPoststeroidsPresteroidsPoststeroids
145.4 (±18.1)42.6 (±20.3)4.1 (±2.1)2.6 (±1.3)3.6 (±0.9)2.4 (±0.6)1516 (±206)1458 (±222)
241.9 (±13.9)49.4 (±19.2)5.3 (±1.8)5.9 (±2.1)5.1 (±0.8)4.9 (±1.1)1133 (±143)1135 (±136)
356.8 (±34.0)58.0 (±32.1)6.2 (±4.2)5.7 (±3.6)4.2 (±1.3)3.8 (±1.5)1684 (±361)1560 (±381)
429.3 (±8.2)29.4 (±9.6)2.5 (±0.9)2.4 (±0.8)3.5 (±0.8)3.4 (±0.8)1060 (±145)951 (±109)
568.5 (±24.5)68.8 (±24.9)5.5 (±2.0)4.5 (±1.5)3.2 (±0.4)2.6 (±0.4)994 (±96)917 (±51)
661.5 (±20.9)70.2 (±31.6)5.1 (±1.8)6.7 (±3.1)3.4 (±0.8)3.9 (±0.9)1268 (±209)1201 (±240)
756.9 (±25.2)62.6 (±28.7)4.8 (±2.1)4.5 (±1.9)3.4 (±0.7)2.9 (±0.6)1300 (±246)1155 (±225)
871.4 (±35.5)51.9 (±27.4)6.4 (±3.5)3.8 (±2.0)3.6 (±1.0)3.0 (±0.5)1229 (±226)1136 (±215)
949.3 (±21.3)52.4 (±21.9)4.3 (±1.9)5.1 (±2.2)3.6 (±0.6)3.9 (±1.0)1353 (±268)1302 (±277)
1049.3 (±22.2)46.5 (±22.7)4.3 (±2.2)4.6 (±2.7)3.5 (±1.3)4.1 (±1.9)914 (±295)907 (±258)
Mean53.0 (±12.7)53.2 (±12.4)4.8 (±1.1)4.6 (±1.4)3.7 (±0.6)3.5 (±0.8)1245 (±236)1172 (±221)
ε (%); P1.2 (±12.8); .95−4.6 (±22.9); .49−5.6 (±16.0); .28−5.8 (±3.8); .001
  • All values are reported as mean (±SD).
    The mean volume of enhancing tumor was 24.8 ± 21.4 × 10 mm.